Clinical Trials
Diabetic Macular Edema
Active Studies
AMARONE (Eyebiotech)
A 2-part Study Consisting Of An Open-label Multiple Ascending Dose (MAD) Safety Study, And A Dose-finding Single-masked Comparative Safety And Preliminary Efficacy Study Of Intravitreal (IVT) EYE103 In A Mixed Population Of Participants With Diabetic Macular Edema (DME) And Neovascular Age-related Macular Degeneration (NVAMD).
PAGODA (Genentech Roche)
A Phase III, Multicenter, Randomized, Visual Assessor-masked, Active-comparator Study Of The Efficacy, Safety, And Pharmacokinetics Of The Port Delivery System With Ranibizumab In Patients With Diabetic Macular Edema.
Completed Studies
BOULEVARD (Genentech)
A Multiple-center, Multiple-dose, Randomized, Active Comparator-controlled, Double-masked, Parallel Group, 28-week Study To Investigate The Safety, Tolerability, Pharmacokinetics, And Efficacy Of RO6867461 Administered Intravitreally In Patients With Diabetic Macular Edema.
DEL MAR (Allegro)
A 6 Month, Phase 2, Multicenter, Randomized, Controlled, Double-masked Clinical Trial Designed To Evaluate The Safety And Exploratory Efficacy Of Luminate (ALG-1001) As Compared To Avastin In The Treatment Of Diabetic Macular Edema.
ENDURANCE IIT (NCRVA & Regeneron)
A 2 Year Investigator Initiated Study On The Long-term Efficacy And Safety Of Intravitreal Aflibercept (Eylea) Injections For The Treatment Of Diabetic Macular Edema In Subjects Who Completed The Three Year VISTA-DME Trial.
GLIMMER (Kodiak)
A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal Aflibercept in Participants with Visual Impairment Secondary to Treatment-naïve Diabetic Macular Edema (DME).
HULK (NCRVA and Regeneron)
A Phase I/II, 6 Month, Open Label Study Of The Safety And Efficacy Of Suprachoroidal CLS-TA Alone Or In Combination With Intravitreal Aflibercept For The Treatment Of Diabetic Macular Edema.
KALAHARI (Oxurion)
A Phase 2, Randomised, Multicentre Study To Assess The Dose Level Of Multiple THR-149 Injections And To Evaluate The Efficacy And Safety Of THR-149 Versus Aflibercept For The Treatment Of Diabetic Macular Oedema (DME).
KESTREL CRTH258B2301 (Novartis)
A Two-Year, Three-Arm, Randomized, Double-Masked, Multicenter, Phase 3 Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Diabetic Macular Edema.
KSI-CL-101 (Kodiak Sciences)
A Phase 1b Open Label, Multi-center Exploratory Study to Investigate the Bioactivity, Ocular and Systemic Safety, Tolerability, and Pharmacokinetics following Single and Multiple Intravitreal Administrations of KSI-301 in Subjects with Wet Age-related Macular Degeneration, Diabetic Macular Edema, and Retinal Vein Occlusion.
PALADIN (Alimera)
A 3 Year, Phase 4 Safety Study Of IOP Signals In Patients With DME Who Are Treated With ILUVIEN (Fluocinolone Acetonide Intravitreal Implant).
PALM (Allergan)
A Phase 2, Six Month Study On The Evaluation Of Abidipar Pegol (AGN-150998) In Patients With Decreased Vision Due To Diabetic Macular Edema.
PROTOCOL U (DRCR Network)
A Short-term (9 Months) Evaluation Of Combination Corticosteroid (Ozurdex) + Anti-vegf (Lucentis) Treatment For Persistent Central-involved Diabetic Macular Edema Following Anti-vegf Therapy.
RHINE GR40398 (Roche)
A Phase 3, Multicenter, Randomized, Double-masked, Active Comparator-controlled Study To Evaluate The Efficacy And Safety Of RO6867461 In Patients With Diabetic Macular Edema.
RHONE (Roche)
A Multicenter, Open-label Extension Study To Evaluate The Long-term Safety And Tolerability Of Faricimab In Patients With Diabetic Macular Edema.
RUBY (Regeneron)
A 9 Month, Phase 2, Randomized, Double-masked Study Of The Efficacy, Safety, And Tolerability Of Repeated Doses Of Intravitreal REGN910-3 In Patients With Diabetic Macular Edema.
VISTA (Regeneron)
A Double-masked, Randomized, Active-controlled, Phase 3 Study Of The Efficacy And Safety Of Intravitreal Administration Of VEGF Trap-eye In Patients With Diabetic Macular Edema.
